- Trial phase
- Approved (FDA June 2023, EMA August 2022), then voluntarily withdrawn February 2026.
- Time to market
- Withdrawn from market as of February 2026; no longer commercially available.
- Why 1/10
- ROCTAVIAN was voluntarily withdrawn from the market on February 23, 2026, and there are no scheduled regulatory or pivotal-readout catalysts for this drug going forward. It is a withdrawn, discontinued asset with no remaining commercial or clinical binary events.
ROCTAVIAN is a withdrawn drug with no remaining commercial presence or regulatory catalysts. BioMarin's stock thesis now rests entirely on VOXZOGO (achondroplasia), its enzyme replacement therapy portfolio, and the recently acquired Alesta Therapeutics pipeline. The Q3 2026 earnings beat (EPS $0.23 vs -$0.08 consensus) shows the company is moving past the ROCTAVIAN failure, but the drug itself is a closed chapter for investors.
Price Chart
Executive Summary
ROCTAVIAN (valoctocogene roxaparvovec) is a one-time gene therapy for severe hemophilia A developed by BioMarin Pharmaceutical (BMRN). It won FDA approval on June 29, 2023, as the first gene therapy for this indication, but was a commercial failure due to its $2.9 million price tag, complex reimbursement logistics, and slow physician/patient adoption. After failing to find a buyer, BioMarin voluntarily withdrew ROCTAVIAN from the market on February 23, 2026, taking roughly $240 million in charges. The drug was available through May 2026 in the US, Germany, and Italy before being fully discontinued. As of November 2026, ROCTAVIAN is a withdrawn asset with no remaining catalysts for investors.
How It Works
ROCTAVIAN is a one-time gene therapy that uses a harmless, modified virus (AAV serotype 5) to deliver a working copy of the gene for factor VIII, a blood-clotting protein that people with severe hemophilia A lack. A single intravenous infusion is designed to enable the patient's own liver cells to produce factor VIII long-term, reducing or eliminating the need for regular factor VIII infusions.
Trial Status
ROCTAVIAN completed Phase 3 (GENEr8-1, NCT03370913) and Phase 1/2 trials demonstrating durable hemostatic efficacy and factor VIII activity for 5+ years. Final 5-year Phase 3 results were published in 2026 confirming no new safety signals. Despite positive clinical data, commercial uptake was negligible due to pricing and reimbursement barriers.
The Two-Sided Case
Upcoming Catalysts
- None. ROCTAVIAN has been withdrawn from the market and is no longer in development or commercialization.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report